165 related articles for article (PubMed ID: 24472365)
1. Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy.
Giaime P; Daniel L; Burtey S
Clin Nephrol; 2015 Jan; 83(1):57-60. PubMed ID: 24472365
[TBL] [Abstract][Full Text] [Related]
2. Rituximab fails where eculizumab restores renal function in C3nef-related DDD.
Rousset-Rouvière C; Cailliez M; Garaix F; Bruno D; Laurent D; Tsimaratos M
Pediatr Nephrol; 2014 Jun; 29(6):1107-11. PubMed ID: 24408225
[TBL] [Abstract][Full Text] [Related]
3. Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.
Von Visger J; Cassol C; Nori U; Franco-Ahumada G; Nadasdy T; Satoskar AA
BMC Nephrol; 2019 Feb; 20(1):53. PubMed ID: 30764798
[TBL] [Abstract][Full Text] [Related]
4. C3 glomerulopathy in children: Is there still a place for anti-cellular immunosuppression?
Kojc N; Bahovec A; Levart TK
Nephrology (Carlton); 2019 Feb; 24(2):188-194. PubMed ID: 30393898
[TBL] [Abstract][Full Text] [Related]
5. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
6. C3 glomerulonephritis with a severe crescentic phenotype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Pediatr Nephrol; 2017 Sep; 32(9):1625-1633. PubMed ID: 28593446
[TBL] [Abstract][Full Text] [Related]
7. Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.
Häffner K; Michelfelder S; Pohl M
Pediatr Nephrol; 2015 Nov; 30(11):1951-9. PubMed ID: 25986912
[TBL] [Abstract][Full Text] [Related]
8. A case of C3 glomerulonephritis successfully treated with eculizumab.
Payette A; Patey N; Dragon-Durey MA; Frémeaux-Bacchi V; Le Deist F; Lapeyraque AL
Pediatr Nephrol; 2015 Jun; 30(6):1033-7. PubMed ID: 25796589
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.
Rudnicki M
Biomed Res Int; 2017; 2017():2180508. PubMed ID: 28573137
[TBL] [Abstract][Full Text] [Related]
10. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.
Guiard E; Karras A; Plaisier E; Duong Van Huyen JP; Fakhouri F; Rougier JP; Noel LH; Callard P; Delahousse M; Ronco P
Clin J Am Soc Nephrol; 2011 Jul; 6(7):1609-16. PubMed ID: 21700823
[TBL] [Abstract][Full Text] [Related]
11. Membranoproliferative glomerulonephritis and C3 glomerulonephritis: frequency, clinical features, and outcome in children.
Okuda Y; Ishikura K; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Fukuzawa R; Ogata K; Honda M
Nephrology (Carlton); 2015 Apr; 20(4):286-92. PubMed ID: 25524631
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive Treatment in C3 Glomerulopathy: Is it Really Effective?
Caliskan Y; Torun ES; Tiryaki TO; Oruc A; Ozluk Y; Akgul SU; Temurhan S; Oztop N; Kilicaslan I; Sever MS
Am J Nephrol; 2017; 46(2):96-107. PubMed ID: 28700996
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy.
Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F
Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752
[TBL] [Abstract][Full Text] [Related]
14. Membranoproliferative glomerulonephritis with C3NeF and genetic complement dysregulation.
Leroy V; Fremeaux-Bacchi V; Peuchmaur M; Baudouin V; Deschênes G; Macher MA; Loirat C
Pediatr Nephrol; 2011 Mar; 26(3):419-24. PubMed ID: 21188423
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab in Pediatric Dense Deposit Disease.
Oosterveld MJ; Garrelfs MR; Hoppe B; Florquin S; Roelofs JJ; van den Heuvel LP; Amann K; Davin JC; Bouts AH; Schriemer PJ; Groothoff JW
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1773-82. PubMed ID: 26316621
[TBL] [Abstract][Full Text] [Related]
16. C3 glomerulopathy.
Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
[TBL] [Abstract][Full Text] [Related]
17. C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.
Ravindran A; Fervenza FC; Smith RJH; Sethi S
Kidney Int; 2018 Jul; 94(1):178-186. PubMed ID: 29729982
[TBL] [Abstract][Full Text] [Related]
18. C3 glomerulopathy and current dilemmas.
Ito N; Ohashi R; Nagata M
Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
[TBL] [Abstract][Full Text] [Related]
19. Recurrent allograft C3 glomerulonephritis and unsuccessful eculizumab treatment.
Kaartinen K; Martola L; Räisänen-Sokolowski A; Meri S
Clin Immunol; 2018 Feb; 187():104-106. PubMed ID: 29097196
[TBL] [Abstract][Full Text] [Related]
20. C3 glomerulopathy: A new complement-based entity.
de Lorenzo A; Tallón S; Hernández-Sevillano B; de Arriba G
Rev Clin Esp (Barc); 2014; 214(5):266-74. PubMed ID: 24576419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]